COMMUNIQUÉS West-GlobeNewswire

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
15/12/2025
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a [...]
SPR Reaches Milestone 50,000th Implant of the SPR® SPRINT® PNS System
15/12/2025
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SPR announced that it has reached 50,000 implants of the SPRINT ® PNS System, a significant milestone recognizing the impact of treatment for patients with 60-day peripheral [...]
BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
15/12/2025
MILAN, 15 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société italienne pionnière en oncologie au stade clinique, développant une solution innovante de radiothérapie pour [...]
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
15/12/2025
MILAN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted [...]
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
15/12/2025
STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
15/12/2025
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente
15/12/2025
Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente Les discussions en cours avec la FDA concernant la demande pour la SEPSPnr indiquent [...]
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
15/12/2025
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for [...]
La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx
15/12/2025
Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour [...]
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer
15/12/2025
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the [...]
Communiqué de presse : Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive
15/12/2025
Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive L'étude de phase 3 PERSEUS dans la sclérose en plaques primaire progressive n'a pas atteint son critère d'évaluation principal de [...]
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15/12/2025
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month [...]
Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI
15/12/2025
December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVue TM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary [...]
NANOBIOTIX va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
15/12/2025
PARIS et CAMBRIDGE, Mass., 15 déc. 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
15/12/2025
PARIS and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand [...]
Byron Medical Announces the Product Release of BlancOne: a Science-Powered Breakthrough Redefining In-Chair Whitening Technology
15/12/2025
BRISBANE, Australia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Byron Medical is excited to announce their exclusive distribution of BlancOne, a system developed with cutting-edge photochemistry and biophotonics that is [...]
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
14/12/2025
– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage [...]
Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods
14/12/2025
Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian biotechnology pioneer Vaxxas [...]
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
14/12/2025
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb [...]

Pages